세계의 흉막 질환 시장 : 질환 유형별, 진단 도구별, 치료법별, 최종 사용자별, 지역별
Pleural Diseases Market, By Disease Type, By Diagnostic Tools, By Treatment Modalities, By End User, By Geography
상품코드
:
1741288
리서치사
:
Coherent Market Insights
발행일
:
2025년 03월
페이지 정보
:
영문
ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
흉막 질환 시장은 2025년에는 57억 6,000만 달러로 평가되었고, 2032년에는 93억 7,000만 달러에 이를 것으로 예측되며, 2025년부터 2032년까지의 연평균 성장률(CAGR)은 7.2%를 나타낼 전망입니다.
| 보고 범위 |
보고서 세부 정보 |
| 기준 연도 |
2024년 |
2025년 시장 규모 |
57억 6,000만 달러 |
| 실적 데이터 |
2020-2024년 |
예측 기간 |
2025-2032년 |
| CAGR(2025-2032년) |
7.20% |
가치 예측(2032년) |
93억 7,000만 달러 |
흉막 질환은 폐를 둘러싸고 있는 얇은 막인 흉막에 영향을 미치는 다양한 질환을 포함합니다. 이러한 질환은 호흡 기능과 전반적인 건강 상태에 심각한 영향을 미칠 수 있습니다. 흉막은 폐의 구조와 기능을 유지하는 데 중요한 역할을 하며, 호흡 시 윤활 작용을 제공하고 부드러운 움직임을 가능하게 합니다. 흉막 질환은 감염, 염증, 종양, 유해 물질 노출 등 다양한 원인으로 발생할 수 있습니다. 일반적인 흉막 질환에는 흉막염, 흉막 삼출, 기흉, 흉막 중피종이 포함됩니다. 증상을 인식하고 정확히 진단하며 적절한 치료 전략을 시행하는 것은 이러한 전 세계적으로 어려운 흉막 질환으로 고통받는 환자의 관리와 예후 개선에 필수적입니다. 전 세계 흉막 질환 시장은 흡연, 결핵, 전이 등 관련 위험 요인의 증가로 인해 최근 몇 년간 꾸준히 성장해 왔습니다. 또한 진단 및 치료 방법(영상 기술 및 레이저 치료 등) 분야의 기술적 진보가 시장 성장을 더욱 촉진하고 있습니다.
시장 역학 :
무기적 전략(협약 등)의 채택이 증가함에 따라 예측 기간 동안 시장 성장이 촉진될 것으로 예상됩니다. 예를 들어, 2020년 11월, 제약 회사인 Taiho Pharmaceutical Co., Ltd.와 임상 단계 바이오제약 회사인 Lung Therapeutics, Inc.는 Lung Tx가 개발 중인 국소성 흉막 삼출액 치료를 위한 재조합 인간 단일 사슬 우로키나제 플라스미노겐 활성화제(LTI-01)에 대한 일본 지역 독점 라이선스 계약을 체결했습니다.
그러나 인식 부족과 진단 지연, 진단 도구 및 치료 비용, 전문 인력과 자원 부족은 예측 기간 동안 세계의 흉막 질환 시장 성장을 방해할 것으로 예상됩니다.
본 조사의 주요 특징
- 본 보고서는 세계의 흉막 질환 시장을 상세하게 분석하여 2024년을 기준 연도으로 한 예측기간 2025-2032년 시장 규모 및 연평균 성장률(CAGR)을 제공합니다.
- 또, 다양한 부문에 걸친 잠재적인 수익 기회를 밝혀, 이 시장의 매력적인 투자 제안 매트릭스에 대해서 해설했습니다.
- 또 시장 성장 촉진요인, 억제요인, 기회, 신제품의 출시 및 승인, 시장 동향, 지역별 전망, 주요 기업이 채택하는 경쟁 전략 등에 관한 중요한 고찰도 제공합니다.
- 기업 하이라이트, 제품 포트폴리오, 주요 하이라이트, 실적, 전략 등의 파라미터를 바탕으로 세계의 흉막 질환 시장의 주요 기업을 프로파일하고 있습니다.
- 이 보고서로부터의 통찰은 기업들의 마케팅 담당자와 경영진이 미래 제품 출시, 제품 업그레이드, 시장 확장, 마케팅 전략 등에 대한 정보 기반 결정을 내리는 데 도움을 줄 것입니다
- 세계의 흉막 질환 시장 보고서는 투자자, 공급업체, 제품 제조업체, 유통 업체, 신규 참가자, 재무 분석가 등이 업계의 다양한 이해 관계자에 대응하고 있습니다.
- 이해관계자는 세계의 흉막 질환 시장 분석에 사용되는 다양한 전략 매트릭스를 통해 의사결정이 용이해집니다.
목차
제1장 조사의 목적과 전제조건
제2장 시장 전망
- 보고서 설명
- 주요 요약
- 일관된 기회 지도(COM)
제3장 시장 역학, 규제, 동향 분석
- 시장 역학
- 호흡기 질환의 이환율 증가
- 전문 인력 및 자원 부족
- 신규 바이오마커 및 정밀 의학의 등장
- 영향 분석
- 주요 하이라이트
- 규제 시나리오
- 제품 출시 및 승인
- PEST 분석
- PORTER 분석
- 합병과 인수 시나리오
제4장 세계의 흉막 질환 시장 : 코로나 바이러스(COVID-19) 팬데믹의 영향
- COVID-19 역학
- 공급 측면 및 수요 측면 분석
- 경제에 미치는 영향
제5장 세계의 흉막 질환 시장 : 질환 유형별(2020-2032년)
제6장 세계의 흉막 질환 시장 : 진단 도구별(2020-2032년)
제7장 세계의 흉막 질환 시장 : 치료법별(2020-2032년)
- 의약품
- 흉강천자 및 흉막고정술
- 최소 침습
- 수술
제8장 세계의 흉막 질환 시장 : 최종 사용자별(2020-2032년)
제9장 세계의 흉막 질환 시장 : 지역별(2020-2032년)
- 북미
- 유럽
- 아시아태평양
- 라틴아메리카
- 중동
- 아프리카
제10장 경쟁 구도
- Bristol Myers Squibb
- Merck & Co., Inc.
- GlaxoSmithKline plc
- Boehringer Ingelheim International GmbH
- Sanofi
- AbbVie Inc.
- Braun SE
- Becton, Dickinson and Company
- Bicakcilar
- Biometrix
- Cook Medical
- Grena
- Redax
- Rocket Medical
- Smith Medical
제11장 섹션
HBR
영문 목차
Pleural Diseases Market is estimated to be valued at USD 5.76 Bn in 2025 and is expected to reach USD 9.37 Bn by 2032, growing at a compound annual growth rate (CAGR) of 7.2% from 2025 to 2032.
| Report Coverage |
Report Details |
| Base Year: |
2024 |
Market Size in 2025: |
USD 5.76 Bn |
| Historical Data for: |
2020 To 2024 |
Forecast Period: |
2025 To 2032 |
| Forecast Period 2025 to 2032 CAGR: |
7.20% |
2032 Value Projection: |
USD 9.37 Bn |
Pleural diseases encompass a diverse group of conditions affecting the pleura, the thin membrane surrounding the lungs. These conditions can significantly impact respiratory function and overall well-being. The pleura plays a crucial role in maintaining the integrity of the lung's structure and function by providing lubrication and allowing smooth movement during breathing. Pleural diseases can arise from various causes, including infections, inflammation, tumors, and exposure to hazardous substances. Common pleural disorders include pleurisy, pleural effusion, pneumothorax and mesothelioma. Recognizing the symptoms, diagnosing accurately, and implementing appropriate treatment strategies are essential in managing and improving outcomes for individuals affected by these challenging global pleural diseases. The Global pleural diseases market has been steadily growing over the years driven by the rising prevalence of associated risk factors such as smoking, tuberculosis, and metastases. Furthermore, the market has witnessed significant technological advancements in diagnosis and treatment modalities such as imaging techniques and laser therapy, further supporting the market growth.
Market Dynamics:
The increasing adoption of inorganic strategies such as agreement is also expected to drive the growth of the market over the forecast period. For instance, in November 2020, Taiho Pharmaceutical Co., Ltd, a pharmaceutical company, and Lung Therapeutics, Inc., a clinical-stage biopharmaceutical company, announced an exclusive license agreement of LTI-01, a recombinant human single-chain urokinase plasminogen activator, currently under development by Lung Tx for loculated pleural effusions, for the territory of Japan.
However, limited awareness and delayed diagnosis, cost of diagnostic tools and treatment, limited availability of expertise and resources are expected to hamper growth of the global pleural diseases market over the forecast period.
Key features of the study:
- This report provides an in-depth analysis of the global pleural diseases market, and provides market size (US$ Mn) and compound annual growth rate (CAGR %) for the forecast period 2025-2032, considering 2024 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the Global Pleural Diseases market based on the following parameters - company highlights, products portfolio, key highlights, financial performance, and strategies
- Key companies covered as a part of this study include Bristol Myers Squibb, Merck & Co., Inc., GlaxoSmithKline plc, Boehringer Ingelheim International GmbH, Sanofi, AbbVie Inc., B. Braun SE, Becton, Dickinson and Company, Bicakcilar, Biometrix, Cook Medical, Grena, Redax, Rocket Medical, Smith Medical.
- Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
- The global pleural diseases market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global pleural diseases market
Global Pleural Diseases Market Segmentation Detailed Segmentation:
- By Disease Types:
- Pleurisy
- Pleural Effusion
- Pneumothelioma
- Mesothelioma
- Others
- By Diagnostic Tools:
- Imaging Techniques
- Molecular Diagnostics
- Thoracoscopy and Pleuroscopy
- By Treatment Modalities:
- Medications
- Thoracentesis and Pleurodesis
- Minimally Invasive Interventions
- Surgical Interventions
- By End User:
- Hospitals and Clinics
- Diagnostic Centers
- Research and Academic Institutions
- By Region:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East
- Africa
- Company Profile:
- Bristol Myers Squibb
- Merck & Co., Inc.
- GlaxoSmithKline plc
- Boehringer Ingelheim International GmbH
- Sanofi
- AbbVie Inc.
- Braun SE
- Becton, Dickinson and Company
- Bicakcilar
- Biometrix
- Cook Medical
- Grena
- Redax
- Rocket Medical
- Smith Medical
Table of Contents
1. Research Objectives and Assumptions
- Research Objectives
- Assumptions
- Abbreviations
2. Market Purview
- Report Description
- Market Definition and Scope
- Executive Summary
- Market Pleural Diseases, By Disease Type
- Market Pleural Diseases, By Diagnostic Tools
- Market Pleural Diseases, By Treatment Modalities
- Market Pleural Diseases, By End User
- Market Pleural Diseases, By Geography/Region
- Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
- Market Dynamics
- Increasing Prevalence of Respiratory diseases
- Limited Availability of Expertise and Resources
- Emerging Biomarkers and Precision Medicine
- Impact Analysis
- Key Highlights
- Regulatory Scenario
- Product launch/Approvals
- PEST Analysis
- PORTER's Analysis
- Merger and Acquisition Scenario
4. Global Pleural Diseases Market - Impact of Coronavirus (COVID-19) Pandemic
- COVID-19 Epidemiology
- Supply Side and Demand Side Analysis
- Economic Impact
5. Global Pleural Diseases Market, By Disease Type, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Pleurisy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Pleural Effusion
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Pneumothelioma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Mesothelioma
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
- Others
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Bn)
6. Global Pleural Diseases Market, By Diagnostic Tools, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Imaging Techniques
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
- Molecular Diagnostics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 20218-2032, (US$ Billion)
- Thoracoscopy and Pleuroscopy
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
7. Global Pleural Diseases Market, By Treatment Modalities, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Medications
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
- Thoracentesis and Pleurodesis
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
- Minimally Invasive Interventions
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
- Surgical Interventions
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
8. Global Pleural Diseases Market, By End User, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, 2021 - 2032
- Segment Trends
- Hospitals and Clinics
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
- Diagnostic Centers
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
- Research and Academic Institutions
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, 2020-2032, (US$ Billion)
9. Global Pleural Diseases Market, By Region, 2020-2032, (US$ Bn)
- Introduction
- Market Share Analysis, By Country, 2025 and 2032 (%)
- Y-o-Y Growth Analysis, For Country 2021 -2032
- Country Trends
- North America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Diagnostic Tools, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Modalities, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- Europe
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Diagnostic Tools, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Modalities, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- Asia Pacific
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Diagnostic Tools, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Modalities, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- Latin America
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Diagnostic Tools, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Modalities, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- Middle East
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Diagnostic Tools, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Modalities, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country, 2020-2032, (US$ Bn)
- Africa
- Introduction
- Market Size and Forecast, and Y-o-Y Growth, By Disease Type, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Diagnostic Tools, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Modalities, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By End User, 2020-2032, (US$ Bn)
- Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2020-2032, (US$ Bn)
10. Competitive Landscape
- Bristol Myers Squibb
- Company Highlights
- Product Portfolio
- Key Developments
- Financial Performance
- Strategies
- Merck & Co., Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- GlaxoSmithKline plc
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Boehringer Ingelheim International GmbH
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Sanofi
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- AbbVie Inc.
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Braun SE
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Becton, Dickinson and Company
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Bicakcilar
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Biometrix
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Cook Medical
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Grena
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Redax
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Rocket Medical
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Smith Medical
- Company Highlights
- Product Portfolio
- Key Highlights
- Financial Performance
- Strategies
- Analyst Views
11. Section
- Research Methodology
- About us
관련자료
